<DOC>
	<DOC>NCT02790736</DOC>
	<brief_summary>The study will test the efficacy of propranolol or placebo, administered after retrieval of a previously acquired public speaking fear, in reducing fear and avoidance of public speaking.</brief_summary>
	<brief_title>Brief Intervention to Reduce Fear of Public Speaking</brief_title>
	<detailed_description>Twenty subjects with Performance-Only type of Social Anxiety Disorder will be enrolled in the study. Participants will complete baseline assessments of fear and avoidance of public speaking. Participants will be randomly assigned to a single dose of propranolol 40mg or placebo, administered immediately after a fear activation procedure. Primary outcome assessment will be self-reported fear of public speaking and avoidance behavior in a behavioral avoidance task 2 weeks after the intervention.</detailed_description>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Principal Diagnosis of Social Anxiety Disorder, Performance only type Has clinically significant fear of public speaking Physically healthy History of other serious psychiatric disorder Current Major Depressive Disorder Women who are pregnant or nursing Current use of psychiatric medication Persons planning to start another treatment during the study period. Any significant medical condition that might increase the risk or participation or use of medications that might negatively interact with propranolol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>propranolol</keyword>
	<keyword>public speaking anxiety</keyword>
</DOC>